1. Azelastine 0.1% nasal spray reduced confirmed SARS-CoV-2 infections compared to placebo.
2. Infection rates: 2% azelastine vs 7% placebo.
3. Participants used the spray three times daily.
4. Adverse events included more bitter taste and nosebleeds for azelastine.
5. Proposed mechanisms include ACE2 interaction and protease inhibition.
6. Limitations: single-centered study, healthy cohort, symptom-triggered testing.

Source: JAMA Internal Medicine